777858-77-2

Upstream product

• 153527-52-7 4-O-acetyl-1,2,3,6-tetra-O-trimethylacetyl-β-D-galactopyranose 
• 777858-76-1 cholesteryl 4-O-acetyl-2,3,6-tri-O-(trimethylacetyl)-β-D-galactopyranoside 
• 777858-75-0 4-O-acetyl-2,3,6-tri-O-(trimethylacetyl)-α-D-galactopyranose 
• 51704-23-5 1-O-cholesteryl-β-D-galactopyranoside 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 777858-78-3 cholesteryl 6-O-(tert-butyl-diphenylsilyl)-3,4-O-isopropylidene-β-D-galactopyranoside 
• 869670-55-3 cholesteryl 3,4-O-isopropylidene-2-O-(4-methoxybenzyl)-β-D-galactopyranoside 
• 777858-79-4 cholesteryl 2-O-allyl-6-O-(tert-butyl-diphenylsilyl)-3,4-O-isopropylidene-β-D-galactopyranoside 
• 869670-52-0 cholesteryl 2-O-allyl-6-O-palmitoyl-β-D-galactopyranoside 
• 869670-62-2 cholesteryl 3,4-O-isopropylidene-2-O-(4-methoxybenzyl)-6-O-oleyl-β-D-galactopyranoside 

Relevant academic research and scientific papers

Synthesis of two glycolipid antigens of the causative agent of Lyme disease

As a prelude to development of a human vaccine against Lyme disease, the first chemical synthesis of glycolipid antigens of Borrelia burkholderi is reported. First, cholesteryl β-d-galactopyranoside was synthesized and was converted to partially protected congeners having the HO-6 group of the galactose moiety unprotected. Treatment of these intermediates with palmitic and oleic acid, respectively, under dehydrative conditions followed by removal of the protecting groups afforded cholesteryl 6-O-palmitoyl/oleoyl-β-d- galactopyranosides that were identical to the glycolipids isolated from B. burkholderi.